




RealRate

PHARMACEUTICAL 2012

Musclepharm Corp
Rank 177 of 196



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Musclepharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Musclepharm Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Musclepharm Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 222% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 206% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	4,017
Cost of Goods Sold	14,471
Intangible Assets	0
Liabilities, Current	17,710
Liabilities, Non-Current	307
Other Assets	122
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-7,061
Other Revenues	20,838
Property and Equipment	908
Research and Development	0
Selling, General and Administrative Expense	22,588

Output Variable	Value in 1000 USD
Assets	5,046
Liabilities	18,017
Expenses	37,058
Revenues	20,838
Stockholders Equity	-12,971
Net Income	-23,281
Comprehensive Net Income	-23,281
BaseVar	44,011
ECR before LimitedLiability	-447%
Economic Capital Ratio	29%